Chelsea Jin is currently a biostatistician at a pharmaceutical company, Bristol Myers Squibb. Working in oncology, she provides strategic statistical supports for developing and delivering world class medications to those who suffer from the deadly disease.

Received regulatory approvals on 5 therapies and 3 diagnostics; delivered 2 compounds to early phase and 3 diagnostics to late phase development.

Authored 30+ peer-reviewed papers, 20+ conference presentations; orally presented in ASA meetings; designed and implemented 6 advanced and innovative solutions and guidelines.

M.D. in Public Health, M.S. in Biophysics, and M.A. in Statistics.

About